Real-life Study on the Use of Allogeneic Hematopoietic Stem Cell Transplantation in Patients With Relapsed/Refractory Multiple Myeloma

Studio Real-life Sull'Utilizzo Del Trapianto Allogenico di Cellule Staminali Ematopoietiche in Pazienti Affetti da Mieloma Multiplo Recidivato Refrattario

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT07777406

Acronym

MAIELLA

Enrollment

Registered

2026-08-20

Start date

2026-03-24

Completion date

2027-12-31

Last updated

2026-08-20

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Plasma Cell Neoplasms

Keywords

multiple myeloma, allogeneic hematopoietic stem cell transplantation

Brief summary

A multicenter, non-interventional, observational, retrospective and prospective pharmacological study aimed at evaluating the use of allogeneic hematopoietic stem cell transplantation in patients with relapsed/refractory multiple myeloma.

Interventions

None listed

Study design

Observational model

COHORT

Time perspective

CROSS_SECTIONAL

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

* patients diagnosed with relapsed/refractory multiple myeloma according to IMWG criteria who have undergone allogeneic hematopoietic stem cell transplantation; * Age ≥ 18 years; * Signature of the informed consent form (where possible).

Exclusion criteria

* Patients diagnosed with primary AL amyloidosis, monoclonal gammopathy of undetermined significance (MGUS), indolent multiple myeloma, or primary plasma cell leukemia; * Patients who have not undergone allogeneic hematopoietic stem cell transplantation; * Age \< 18 years.

Design outcomes

Primary

Measure	Time frame	Description
Progression-free survival (PFS)	10 years from the date of allogeneic hematopoietic stem cell transplantation.	Progression-free survival (PFS) of patients with relapsed/refractory multiple myeloma undergoing allogeneic hematopoietic stem cell transplantation. PFS is defined as time from the date of allogeneic hematopoietic stem cell transplantation to the date of confirmed disease progression, or the date of death from any cause, whichever comes first.

Countries

Italy

Contacts

CONTACTCarmine Liberatore, MD

carmine.liberatore@unich.it+390854252853

Outcome results